Beta Bionics Inc’s filing revealed that its Chief Product Officer Mensinger Mike acquired Company’s shares for reported $0.57 million on Jan 31 ’25. In the deal valued at $17.00 per share,33,350 shares were bought. As a result of this transaction, Mensinger Mike now holds 59,019 shares worth roughly $0.95 million.
Then, Mensinger Mike sold 13 shares, generating $221 in total proceeds. Upon selling the shares at $17.00, the Chief Product Officer now owns 25,669 shares.
Before that, Wellington Hadley Harbor Aggre bought 1,000,000 shares. Beta Bionics Inc shares valued at $17,000,000 were divested by the 10% Owner at a price of $17.00 per share. As a result of the transaction, Wellington Hadley Harbor Aggre now holds 3,901,599 shares, worth roughly $62.97 million.
Stifel initiated its Beta Bionics Inc [BBNX] rating to a Buy in a research note published on February 24, 2025; the price target was $25. A number of analysts have revised their coverage, including Piper Sandler’s analysts, who began to cover the stock in late February with a ‘”an Overweight”‘ rating. Leerink Partners began covering BBNX with “an Outperform” recommendation on February 24, 2025. Lake Street started covering the stock on February 24, 2025. It rated BBNX as “a Buy”.
Price Performance Review of BBNX
On Friday, Beta Bionics Inc [NASDAQ:BBNX] saw its stock fall -9.38% to $16.14. Over the last five days, the stock has lost -23.03%. Beta Bionics Inc shares have fallen nearly -31.70% since the year began.
Levels Of Support And Resistance For BBNX Stock
The 24-hour chart illustrates a support level at 15.41, which if violated will result in even more drops to 14.67. On the upside, there is a resistance level at 17.32. A further resistance level may holdings at 18.49. The Moving Average Convergence Divergence (MACD) stands at -2.47, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 95.47%. Stochastics %K at 14.44% indicates the stock is a buying.
The most recent change occurred on February 24, 2025 when BofA Securities began covering the stock and recommended ‘”a Buy”‘ rating .
